We are pleased to invite you to read the notable papers in the field of lung cancer chemotherapy in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information for this field. The list of relevant papers is provided below.

“Real-World Treatment Outcomes and Safety of Afatinib in Advanced Squamous Cell Lung Cancer Progressed after Platinum-Based Doublet Chemotherapy and Immunotherapy (SPACE Study)”
by Wonjun Ji, In-Jae Oh, Cheol-Kyu Park, Sung Yong Lee, Juwhan Choi, Jae Cheol Lee, Jiwon Kim and Seung Hyeun Lee
Cancers 2023, 15(23), 5568; https://doi.org/10.3390/cancers15235568
Available online: https://www.mdpi.com/2072-6694/15/23/5568

“PD-1/PD-L1 Inhibitors plus Chemotherapy Versus Chemotherapy Alone for Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”
by Eric Pasqualotto, Francisco Cezar Aquino de Moraes, Matheus Pedrotti Chavez, Maria Eduarda Cavalcanti Souza, Anna Luíza Soares de Oliveira Rodrigues, Rafael Oliva Morgado Ferreira, Lucca Moreira Lopes, Artur Menegaz de Almeida, Marianne Rodrigues Fernandes and Ney Pereira Carneiro dos Santos
Cancers 2023, 15(21), 5143; https://doi.org/10.3390/cancers15215143
Available online: https://www.mdpi.com/2072-6694/15/21/5143

“Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study”
by Keiko Tanimura, Takayuki Takeda, Akihiro Yoshimura, Ryoichi Honda, Shiho Goda, Shinsuke Shiotsu, Mototaka Fukui, Yusuke Chihara, Kiyoaki Uryu, Shota Takei et al.
Cancers 2023, 15(17), 4358; https://doi.org/10.3390/cancers15174358
Available online: https://www.mdpi.com/2072-6694/15/17/4358

“Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study”
by Takayuki Takeda, Tadaaki Yamada, Yusuke Kunimatsu, Keiko Tanimura, Kenji Morimoto, Shinsuke Shiotsu, Yusuke Chihara, Asuka Okada, Shigeto Horiuchi, Makoto Hibino et al.
Cancers 2023, 15(5), 1543; https://doi.org/10.3390/cancers15051543
Available online: https://www.mdpi.com/2072-6694/15/5/1543

“The Role of Immunotherapy or Immuno-Chemotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review”
by Shehab Mohamed, Luca Bertolaccini, Domenico Galetta, Francesco Petrella, Monica Casiraghi, Filippo de Marinis and Lorenzo Spaggiari
Cancers 2023, 15(9), 2476; https://doi.org/10.3390/cancers15092476
Available online: https://www.mdpi.com/2072-6694/15/9/2476

“First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study”
by Keiko Tanimura, Takayuki Takeda, Nobutaka Kataoka, Akihiro Yoshimura, Kentaro Nakanishi, Yuta Yamanaka, Hiroshige Yoshioka, Ryoichi Honda, Kiyoaki Uryu and Mototaka Fukui
Cancers 2023, 15(20), 4988; https://doi.org/10.3390/cancers15204988
Available online: https://www.mdpi.com/2072-6694/15/20/4988

“Blood Immune Cells as Biomarkers in Long-Term Surviving Patients with Advanced Non-Small-Cell Lung Cancer Undergoing a Combined Immune/Chemotherapy”
by Miriam Möller, Wolfgang Schütte, Steffi Turzer, Barbara Seliger and Dagmar Riemann
Cancers 2023, 15(19), 4873; https://doi.org/10.3390/cancers15194873
Available online: https://www.mdpi.com/2072-6694/15/19/4873

“Nivolumab after Induction Chemotherapy in Previously Treated Non-Small-Cell Lung Cancer Patients with Low PD-L1 Expression”
by Beung-Chul Ahn, Charny Park, Sang-Jin Lee, Sehwa Hong, Ji-Eun Hwang, Kyoungsuk Kwon, Jin Young Kim, Kyung-Hee Kim, Hyae Young Kim, Geon Kook Lee et al.
Cancers 2023, 15(18), 4460; https://doi.org/10.3390/cancers15184460
Available online: https://www.mdpi.com/2072-6694/15/18/4460

“The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy”
by Erkan Topkan, Ugur Selek, Berrin Pehlivan, Ahmet Kucuk, Duriye Ozturk, Beyza Sirin Ozdemir, Ali Ayberk Besen and Huseyin Mertsoylu
Cancers 2023, 15(18), 4512; https://doi.org/10.3390/cancers15184512
Available online: https://www.mdpi.com/2072-6694/15/18/4512

“Clinical Characteristics, Response to Platinum-Based Chemotherapy and Poly (Adenosine Phosphate-Ribose) Polymerase Inhibitors in Advanced Lung Cancer Patients Harboring BRCA Mutations”
by Johnathan Arnon, Michael Tabi, Yakir Rottenberg, Aviad Zick, Philip Blumenfeld, Tamar Hamburger, Eli Pikarsky, Eti Avraham, Leeby Levine, Aron Popovtzer et al.
Cancers 2023, 15(19), 4733; https://doi.org/10.3390/cancers15194733
Available online: https://www.mdpi.com/2072-6694/15/19/4733

“Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy”
by Magdalena Zaborowska-Szmit, Sebastian Szmit, Marta Olszyna-Serementa, Paweł Badurak, Katarzyna Zajda, Anna Janowicz-Żebrowska, Aleksandra Piórek, Magdalena Knetki-Wróblewska, Piotr Jaśkiewicz, Adam Płużański et al.
Cancers 2023, 15(4), 1277; https://doi.org/10.3390/cancers15041277
Available online: https://www.mdpi.com/2072-6694/15/4/1277

You are invited to view and submit relevant papers to the journal Cancers.

Cancers Editorial Office